Is Xylazine safe for dogs and cats?
Moderate risk for petsXylazine is used in dogs as a pre-anesthetic agent, short-term sedative, and component of balanced anesthesia protocols. Dogs require substantially higher doses than cats (1.1–2.2 mg/kg IM) to achieve comparable sedation. The cardiovascular effects — bradycardia, sinus arrhythmia, first- and second-degree AV block, transient hypertension followed by hypotension — are the primary clinical concerns and require monitoring. Respiratory depression can occur and is dose-dependent. The alpha-2 agonist mechanism also causes decreased gastrointestinal motility, increased urination (via inhibition of ADH release), and analgesic effects. Atropine pretreatment to prevent bradycardia is used in some protocols, though this approach is debated. Atipamezole provides effective reversal. Dogs can be induced to vomit with xylazine but with less reliability than cats. At therapeutic veterinary doses, xylazine toxicity is manageable; the principal risks are cardiovascular depression in compromised animals and inadequate monitoring during recovery.
What is xylazine?
The IUPAC name is N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine.
Also known as: N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine, Xilazina, Chanazine, Xylazinum.
- IUPAC name
- N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
- CAS number
- 7361-61-7
- Molecular formula
- C12H16N2S
- Molecular weight
- 220.34 g/mol
- SMILES
- CC1=C(C(=CC=C1)C)NC2=NCCCS2
- PubChem CID
- 5707
Risk for dogs
Moderate riskXylazine is used in dogs as a pre-anesthetic agent, short-term sedative, and component of balanced anesthesia protocols. Dogs require substantially higher doses than cats (1.1–2.2 mg/kg IM) to achieve comparable sedation. The cardiovascular effects — bradycardia, sinus arrhythmia, first- and second-degree AV block, transient hypertension followed by hypotension — are the primary clinical concerns and require monitoring. Respiratory depression can occur and is dose-dependent. The alpha-2 agonist mechanism also causes decreased gastrointestinal motility, increased urination (via inhibition of ADH release), and analgesic effects. Atropine pretreatment to prevent bradycardia is used in some protocols, though this approach is debated. Atipamezole provides effective reversal. Dogs can be induced to vomit with xylazine but with less reliability than cats. At therapeutic veterinary doses, xylazine toxicity is manageable; the principal risks are cardiovascular depression in compromised animals and inadequate monitoring during recovery.
Risk for cats
Moderate riskXylazine (Rompun) is an alpha-2 adrenergic agonist sedative-analgesic that produces a distinctive and uniquely strong emetic response in cats — exploited clinically as a reliable emetic for poisoning decontamination before safer alternatives became available. This emetic response is mediated by alpha-2 receptor stimulation in the chemoreceptor trigger zone (CRTZ), and cats are approximately 10 times more sensitive than dogs to this effect. At sedative doses (0.5–1.1 mg/kg IM), xylazine produces dose-dependent CNS depression, bradycardia, hypotension, hypothermia, respiratory depression, and muscle relaxation in cats. The cardiovascular effects (bradycardia, second-degree AV block, peripheral vasoconstriction followed by vasodilation) require monitoring in compromised cats. Reversal with atipamezole (alpha-2 antagonist) is highly effective. Cats are generally considered more sensitive than dogs to xylazine's cardiovascular and respiratory effects, requiring lower doses. Xylazine should be used with particular caution in cats with hepatic or renal disease.
Regulatory consensus
2 regulatory and scientific bodies have classified Xylazine. The classifications differ — that's the data.
| Agency | Year | Classification | Notes |
|---|---|---|---|
| EPA CTX / Skin-Eye | — | Eye Irritation: Category 6.4A (Category 2A) (score: high) | |
| EPA CTX / Skin-Eye | — | Skin Irritation: Category 6.3A (Category 2) (score: high) |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where pets encounter xylazine
- Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
- Occupational Environments — Factories, Warehouses, Transportation vehicles
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Xylazine:
-
Therapeutic alternatives (consult prescriber)
Trade-offs: Drug-specific. Cannot substitute without medical guidance.Relative cost: 1.2-2×
Frequently asked questions
Is xylazine safe for pets?
Xylazine is used in dogs as a pre-anesthetic agent, short-term sedative, and component of balanced anesthesia protocols. Dogs require substantially higher doses than cats (1.1–2.2 mg/kg IM) to achieve comparable sedation. The cardiovascular effects — bradycardia, sinus arrhythmia, first- and second-degree AV block, transient hypertension followed by hypotension — are the primary clinical concerns and require monitoring. Respiratory depression can occur and is dose-dependent. The alpha-2 agonist mechanism also causes decreased gastrointestinal motility, increased urination (via inhibition of ADH release), and analgesic effects. Atropine pretreatment to prevent bradycardia is used in some protocols, though this approach is debated. Atipamezole provides effective reversal. Dogs can be induced to vomit with xylazine but with less reliability than cats. At therapeutic veterinary doses, xylazine toxicity is manageable; the principal risks are cardiovascular depression in compromised animals and inadequate monitoring during recovery.
What products contain xylazine?
Xylazine appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).
See Xylazine in the pets app
Look up products containing xylazine, compare to alternatives, and explore the full data record.
Open in pets View raw API dataSources (3)
- US FDA: Xylazine — Veterinary Sedative Use, Alpha-2 Agonist Mechanism, Species Dose Differences, Cardiovascular Monitoring Requirements, Atipamezole Reversal, and 2023 Safety Alert Regarding Illicit Drug Supply Adulteration (2023) (2023) — regulatory
- US CDC: Xylazine in the Illicit Drug Supply — Prevalence in Fentanyl Mixtures (Tranq), Naloxone Non-Reversal of Alpha-2 Agonist Effects, Necrotic Wound Syndrome, Overdose Management, and National Spread from Philadelphia (2023) (2023) — regulatory
- ASPCA Animal Poison Control Center: Xylazine in Dogs and Cats — Emetic Response in Cats, Cardiovascular Effects, Dose Comparison, and Atipamezole Reversal (2021) (2021) — veterinary
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →